Frank Navetta, MD
Interventional Cardiology · Tyler, TXNPI 1811982986
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,825 of the $32,227 with a category attached, or 77.0%. Medtronic accounts for 86.3% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $27,863, more than ten times the $927 reported in 2019.
Across 324 payments — averaging $99.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$28K
- Novartis$1K
- Amgen$948
- Boston Scientific$315
- Johnson & Johnson$251
- Amarin Pharma, Inc.$170
- plus $1K from 25 others
Across 41 payments — averaging $33,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1.4M
What the payments were for
- Consulting fees$400%
- Speaking & faculty fees$24,82577%
- Travel & lodging$1,9936%
- Food & beverage$5,36917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $27,815 |
| Novartis | 88 | $1,402 |
| Amgen | 59 | $948 |
| Boston Scientific | 15 | $315 |
| Johnson & Johnson | 19 | $251 |
| Amarin Pharma, Inc. | 10 | $170 |
| Merck | 8 | $156 |
| Cardiovascular Systems Inc. | 9 | $136 |
| Shockwave Medical, Inc | 4 | $105 |
| AstraZeneca | 7 | $94 |
| Abbott | 3 | $71 |
| Bayer | 5 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $67 |
| Cook Medical LLC | 4 | $65 |
| Irhythm Technologies, Inc. | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 5 | $58 |
| Pfizer | 4 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Cvrx, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Philips North America LLC | 2 | $30 |
| Lundbeck LLC | 2 | $28 |
| Cardiva Medical, Inc. | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Surmodics, Inc. | 2 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$25,035
How this compares
$32,227 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 253 | $264,111 |
| XareltoRivaroxaban | 130 | $120,699 |
| EntrestoSacubitril/Valsartan | 81 | $88,792 |
| Repatha SureclickEvolocumab | 71 | $44,217 |
| JardianceEmpagliflozin | 59 | $40,547 |
| BrilintaTicagrelor | 16 | $14,373 |
| Praluent PenAlirocumab | 26 | $13,422 |
| MultaqDronedarone Hcl | 12 | $8,926 |
| Metoprolol Succinate | 209 | $3,940 |
| LivaloPitavastatin Calcium | 12 | $3,865 |
| Ezetimibe | 169 | $3,578 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 272 | $3,535 |
| Potassium Chloride | 155 | $3,496 |
| Carvedilol | 281 | $3,346 |
| ClopidogrelClopidogrel Bisulfate | 274 | $3,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $58 | $264,111253 claims |
| Johnson & JohnsonXarelto | $251 | $120,699130 claims |
| NovartisEntresto | $1,402 | $88,79281 claims |
| Boehringer IngelheimJardiance | $33 | $40,54759 claims |
| AstraZenecaBrilinta | $94 | $14,37316 claims |
| Sanofi-aventis U.S. LLCMultaq | $49 | $8,92612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Tyler
- Jeffrey CarrTyler$1.9M
- Preetham Reddy MuskulaTyler$91K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.